EUVIMEDEUVIMED entdecken
Open Access

Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes

Yichen E Fang iD, Julie M Paik iD, Janinne Ortega-Montiel, Helen Tesfaye iD, Deborah J Wexler, Elisabetta Patorno iD

Diabetes Care · 2025

DOI: 10.2337/dc25-1840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2025. Verfasst von Yichen E Fang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Pancreatitis, Incretins, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, FDA HHS, Patient-Centered Outcomes Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the association between incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is), and these outcomes. We examined the association between incretin medication use and risk of incident AP or biliary disease in patients with T2D. RESEARCH DESIGN AND METHODS Using Medicare Fee-for-Service (FFS) and two U.S. commercial claims databases (2014–2021), we identified three pairwise cohorts of propensity score (PS)–based fine stratification–weighted patients aged ≥18 years (≥65 years in Medicare FFS) with T2D without prior AP or biliary disease who initiated treatment with GLP-1RAs versus sodium–glucose cotransporter 2 inhibitors (SGLT2is), DPP-4is versus SGLT2is, or GLP-1RAs versus DPP-4is. PS was estimated using 92 covariates. Weighted hazard ratios (HRs) with 95% CIs for hospitalization because of AP and biliary events were estimated using Cox models. RESULTS Each cohort included >1.2 million patients. After weighting, GLP-1RA and DPP-4i initiators had similar risk of AP compared with SGLT2i initiators (HR 1.01; 95% CI 0.90–1.13 and HR 1.00; 95% CI 0.85–1.15, respectively). However, both GLP-1RA and DPP-4i initiators showed a modestly increased risk of biliary disease compared with SGLT2i initiators (HR 1.15; 95% CI 1.05–1.26 and HR 1.22; 95% CI 1.03–1.46, respectively), equivalent to fewer than one additional event per 1,000 person-years. There was no difference in risk of AP (HR 1.08; 95% CI 0.95–1.22) or biliary disease (HR 0.95; 95% CI 0.86–1.04) between GLP-1RAs and DPP-4is. CONCLUSIONS In patients with T2D, GLP-1RAs and DPP-4is were associated with a small increase in risk of biliary disease, but not of AP, compared with SGLT2is.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2PancreatitisIncretinsHypoglycemic AgentsHumansMaleFemaleAgedDipeptidyl-Peptidase IV InhibitorsMiddle AgedGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsUnited States

Substanzen

IncretinsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA.
  • Diabetes Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

ORCID-Profile: Yichen E Fang, Julie M Paik, Helen Tesfaye, Elisabetta Patorno

Förderung

  • NIDDK NIH HHS
  • FDA HHS
  • Patient-Centered Outcomes Research Institute

Zitieren

APA

Fang, Y. E., Paik, J. M., Ortega-Montiel, J., Tesfaye, H., Wexler, D. J., & Patorno, E. (2025). Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc25-1840

Vancouver

Fang YE, Paik JM, Ortega-Montiel J, Tesfaye H, Wexler DJ, Patorno E. Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes. Diabetes Care. 2025. doi:10.2337/dc25-1840

BibTeX
@article{Fang2025,
  author = {Fang, Yichen E and Paik, Julie M and Ortega-Montiel, Janinne and Tesfaye, Helen and Wexler, Deborah J and Patorno, Elisabetta},
  title = {Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc25-1840}
}
Kostenlos starten →